Материал: Дерматовенерология (2015)

11.

Glazenburg E. J., Wolkerstorfer A., Gerretsen A. L. et al. Efficacy and safety of

fluticasone propionate 0.005% ointment in the long-term maintenance treat-

ment of children with atopic dermatitis: differences between boys and girls?

Pediatr Allergy Immunol 2009; 20: 59—66.

12.

Tan B., Weald D., Strickland I., Friedman P. Double-blind controlled trial of

effect of housedust-mite allergen avoidance on atopic dermatitis. Lancet 1996;

347: 15—18.

13.

Vocks E., Borelli S., Rakoski J. Climatotherapy in atopic dermatitis. Aller-

gologie 1994; 17: 208—213.

14.

Engst R., Vocks E. Hochgebirgsklimatherapie bei Dermatosen und Allergien

Wirkmechanismen, Ergebnisse und Einflüsse auf immunologische Param-

eter. Rehabilitation 2000; 39: 215—222.

15.

Eberlein B., Gulyas A. F., Schultz K. et al. Domestic allergens and endotoxin

in three hospitals offering in-patient rehabilitation for allergiс diseases in the

alpine mountain climate of Bavaria — the AURA study. Int J Hyg Environ

Health 2009; 212: 21—26.

16.

Hoare C., Li Wan Pо A., Williams H. Systematic review of treatments for

atopic eczema. Health Technol Assess 2000; 4: 1—191.

17.

Wollenberg A., Frank R., Kroth J. et al. Proactive therapy of atopic eczema —

an evidence-based concept with a behavioral background. J Dtsch Dermatol

Ges 2009; 7: 117—121.

18.

27 Patient UK — Fingertip Units for Topical Steroids. [Online]. (URL www.

patient.co.uk/showdoc/27000762) (Accessed 12 February 2007).

19.

Devillers A. C., Oranje A. P. Efficacy and safety of ‘wet-wrap’ dressings as an in-

tervention treatment in children with severe and ⁄ or refractory atopic dermatitis:

a critical review of the literature. Br J Dermatol 2006; 154: 579—585.

20.

Schnopp C., Holtmann C., Stock S. et al. Topical steroids under wetwrap

dressings in atopic dermatitis-a vehicle-controlled trial. Dermatology 2002;

204: 56—59.

21.

Van der Meer J. B., Glazenburg E. J., Mulder.PG. et al. The management of

moderate to severe atopic dermatitis in adults with topical fluticasone propio-

nate. The Netherlands Adult Atopic Dermatitis Study Group. Br J Dermatol

1999; 140: 1114—1121.

22.

Wollenberg A., Bieber T. Proactive therapy of atopic dermatitis — an emerging

concept. Allergy 2009; 64: 276—278.

дерматит

23.

Hanifin J., Gupta A. K., Rajagopalan R. Intermittent dosing of fluticasone

propionate cream for reducing the risk of relapse in atopic dermatitis patients.

Br J Dermatol 2002; 147: 528—537.

Атопический

24.

Walsh P., Aeling J., Huff L., Weston W. Hypothalamus-pituitary-adrenal axis

25.

Queille C., Pommarede R., Saurat J.-H. Efficacy versus systemic effects of

six topical steroids in the treatment of atopic dermatitis of childhood. Pediatr

Dermatol 1984; 1: 246—253.

26.

Charman C., Williams H. The use of corticosteroids and corticosteroid phobia

in atopic dermatitis. Clin Dermatol 2003; 21: 193—200.

27.

Peserico A., Städtler G., Sebastian M. et al. Reduction of relapses of atopic

dermatitis with methylprednisolone aceponate cream twice weekly in adddi-

tion to maintenance treatment with emollient: a multicentre, randomized,

double-blind, controlled study. Br J Dermatol 2008; 158: 801—807.

28.

Kawashima M., Tango T., Noguchi T. et al. Addition of fexofenadine to a topi-

cal corticosteroid reduces the pruritus associated with atopic dermatitis in a

1-week randomized, multicentre, double-blind, placebo-controlled, parallel-

group study. Br J Dermatol 2003; 148: 1212—1221.

29.

Alomar A., Berth-Jones J., Bos J. D. et al. The role of topical calcineurin in-

hibitors in atopic dermatitis. Br J Dermatol 2004; 151 (Suppl. 70): 3—27.

30.

Ruzicka T., Bieber T., Schöpf E. et al. A short-term trial of tacrolimus oint-

ment for atopic dermatitis. N Engl J Med 1997; 337: 816—821.

31.

Van Leent E. J., Graber M., Thurston M. et al. Effectiveness of the ascomycin

macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch

Dermatol 1998; 134: 805—809.

32.

Reitamo S., Wollenberg A., Schöpf E. et al. Safety and efficacy of 1 year of

tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch Der-

matol 2000; 136: 999—1006.

33.

Meurer M., Fölster-Holst R., Wozel G. et al. Pimecrolimus cream in the long-

term management of atopic dermatitis in adults: a six-month study. Dermatol-

ogy 2002; 205: 271—277.

34.

Wollenberg A., Reitamo S., Girolomoni G. et al. Proactive treatment of atopic

dermatitis in adults with 0.1% tacrolimus ointment. Allergy 2008; 63: 742—

750.

35.

Thaci D., Reitamo S., Gonzalez Ensenat M. A. et al. Proactive disease man-

agement with 0.03% tacrolimus ointment for children with atopic dermatitis:

results of a randomized, multicentre, comparative study. Br J Dermatol 2008;

159: 1348—1356.

36.

Reitamo S., Rustin M., Ruzicka T. et al. Efficacy and safety of tacrolimus oint-

ment compared with hydrocortisone butyrate ointment in adult patients with

atopic dermatitis. J Allergy Clin Immunol 2002; 109: 547—555.

37.

Chen S. L., Yan J., Wang F. S. Two topical calcineurin inhibitors for the treat-

кожи

ment of atopic dermatitis in pediatric patients: a meta-analysis of randomized

38.

clinical trials. J Dermatolog Treat 2010; 21: 144—156.

Болезни

Bornhövd E. C., Burgdorf W. H., Wollenberg A. Immunomodulatory macro-

tig Drugs 2002; 3: 708—712.

lactams for topical treatment of inflammatory skin diseases. Curr Opin Inves-

39.

Lübbe J., Pournaras C. C., Saurat J. H. Eczema herpeticum during treatment

of atopic dermatitis with 0.1% tacrolimus ointment. Dermatology 2000; 201:

249—251.

40.

Wetzel S., Wollenberg A. Eczema molluscatum in tacrolimus treated atopic

dermatitis. Eur J Dermatol 2004; 14: 73—74.

41.

Wahn U., Bos J., Goodfield M. et al. Efficacy and safety of pimecrolimus

cream in the long-term management of atopic dermatitis in children. Pediat-

rics 2002; 110: 1—8.

42.

Lubbe J. Klinische Erfahrungen mit topischen Calcineurininhibitoren in der

Praxis. Hautarzt 2003; 54: 432—439.

43.

Bornhovd E., Wollenberg A. Topische Immunmodulatoren zur Ekzembe­

handlung. Allergo J 2003; 12: 456—462.

44.

Reitamo S., Ortonne J. P., Sand C. et al. A multicentre, randomized, double-

blind, controlled study of long-term treatment with 0.1% tacrolimus ointment

in adults with moderate to severe atopic dermatitis. Br J Dermatol 2005; 152:

1282—1289.

45.

Reitamo S., Rissanen J., Remitz A. et al. Tacrolimus ointment does not affect

collagen synthesis: results of a single-center randomized trial. J Invest Derma-

tol 1998; 111: 396—398.

46.

Queille-Roussel C., Paul C., Duteil L. et al. The new topical ascomycin de-

rivative SDZ ASM 981 does not induce skin atrophy when applied to normal

skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol

2001; 144: 507—513.

47.

Arellano F. M., Wentworth C. E., Arana A. et al. Risk of lymphoma following

exposure to calcineurin inhibitors and topical steroids in patients with atopic

dermatitis. J Invest Dermatol 2007; 127: 808—816.

48.

Margolis D. J., Hoffstad O., Bilker W. Lack of association between exposure

to topical calcineurin inhibitors and skin cancer in adults. Dermatology 2007;

214: 289—295.

49.

Ring J., Barker J., Behrendt H. et al. Review of the potential photococarcino-

genicity of topical calcineurin inhibitors. J Eur Acad Dermatol Venereol 2005;

19: 663—671.

50.

Thaci D., Salgo R. Malignancy concerns of topical calcineurin inhibitors for

atopic dermatitis: facts and controversies. Clin Dermatol 2010; 28: 52—56.

дерматит

51.

Patel R. R., Vander Straten M. R., Korman N. J. The safety and efficacy of ta-

crolimus therapy in patients younger than 2 years with atopic dermatitis. Arch

Dermatol 2003; 139: 1184—1186.

Атопический

52.

Reitamo S., Mandelin J., Rubins A. et al. The pharmacokinetics of tacrolimus

53.

Ho V. C., Gupta A., Kaufmann R. et al. Safety and efficacy of nonsteroid

pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pe-

diatr 2003; 142: 155—162.

54.

Eichenfield L. F., Lucky A. W., Boguniewicz M. et al. Safety and efficacy of

pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate

atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002; 46:

495—504.

55.

Reitamo S., Rustin M., Harper J. et al. A 4-year follow-up study of atopic der-

matitis therapy with 0.1% tacrolimus ointment in children and adult patients.

Br J Dermatol 2008; 159: 942—951.

56.

Langley R. G., Eichenfield L. F., Lucky A. W. et al. Sustained efficacy and

safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to

treat children withatopic dermatitis. Pediatr Dermatol 2008; 25: 301—307.

57.

Wollenberg A., Sidhu M. K., Odeyemi I. et al. Economic evaluation of second-

ary prophylactic treatment with tacrolimus 0.1% ointment in adults with moder-

ate to severe atopic dermatitis. Br J Dermatol 2008; 159: 1322—1330.

58.

Thaci D., Chambers C., Sidhu M. et al. Twice-weekly treatment with tacro-

limus 0.03% ointment in children with atopic dermatitis: clinical efficacy and

economic impact over 12 months. J Eur Acad Dermatol Venereol 2010; 24:

1040—1046.

59.

Healy E., Bentley A., Fidler C., Chambers C. Cost-effectiveness of tacrolimus

ointment in adults and children with moderate and severe atopic dermatitis:

twice-weekly maintenance treatment vs. standard twicedaily reactive treat-

ment of exacerbations from a third party payer (U. K. National Health Ser-

vice) perspective. Br J Dermatol 2011; 164: 387—395.

60.

Mandelin J. M., Remitz A., Virtanen H. M. et al. A 10-year open follow-up of

eczema and respiratory symptoms in patients with atopic dermatitis treated with

topical tacrolimus for the first 4 years. J Dermatolog Treat 2010; 21: 167—170.

61.

Mandelin J., Remitz A., Virtanen H. M. et al. One-year treatment with 0.1%

tacrolimus ointment versus a corticosteroid regimen in adults with moderate to

severe atopic dermatitis: a randomized, double-blind, comparative trial. Acta

Derm Venereol 2010; 90: 170—174.

62.

Boguniewicz M., Fiedler V. C., Raimer S. et al. A randomized, vehicle-con-

trolled trial of tacrolimus ointment for treatment of atopic dermatitis in chil-

dren. Pediatric Tacrolimus Study Group. J Allergy Clin Immunol 1998; 102:

кожи

637—644.

63.

Nakagawa H., Etoh T., Ishibashi Y. et al. Tacrolimus ointment for atopic der-

Болезни

matitis. Lancet 1994; 344: 883.

64.

Luger T., van Leent E. J., Graeber M. et al. SDZ ASM 981: an emerging safe

and effective treatment for atopic dermatitis. Br J Dermatol 2001;144: 788—794.

65.

Eichenfield L. F., Thaci D., de Prost Y. et al. Clinical management of atopic

eczema with pimecrolimus cream 1% (Elidel) in paediatric patients. Derma-

tology 2007; 11: 3—17.

66.

Прошутинская Д. В., Бутарева М. М., Иноятова Л. А. Новые возможно-

сти терапии атопического дерматита у детей и взрослых. Вестн дерма-

тол венерол 2013; 3: 78—82.

67.

Самцов А. В., Сухарев А. В., Патрушев А. В., Бондарь О. И. Клиниче-

ская эффективность, безопасность и переносимость 0,1% мази такро-

лимус при лечении атопического дерматита средней и тяжелой степени

тяжести. Вестн дерматол венерол 2012; 2: 71—77.

68.

Самцов А. В., Сухарев А. В., Патрушев А. В. Лечение атопического дер-

матита: преимущества такролимуса перед топическими кортикостеро-

идами. Эффективная фармакотерапия 2014; 19: 4—10.

69.

Кубанов А. А., Петровский Ф. И. Активированный пиритион цинка

(Скин-кап). Механизмы действия. Клиническое применение. Вестн

дерматол венерол 2009; 5: 35—42.

70.

Фассахов Р. С., Пампура А. Н., Коростовцев Д. С. и др. Скин-кап в тера-

пии атопического дерматита у детей (по результатам Российского мно-

гоцентрового исследования КАДЕТ). Рос Аллергол журн 2007; 2: 75—81.

71.

Фассахов Р. С., Пампура А. Н., Коростовцев Д. С. и др. Эффективность

и безопасность активированного цинк пиритиона (скин-кап) в лече-

нии атопического дерматита у детей (результаты российского много-

центрового исследования). Вестн педиатр фармакол нутрициол 2006; 3

(6): 28—31.

72.

Williams H. C., Grindlay D. J. What’s new in atopic eczema? An analysis of

the clinical significance of systematic reviews on atopic eczema published in

2006 and 2007. Clin Exp Dermatol 2008; 33: 685—688.

73.

Gambichler T., Othlinghaus N., Tomi N. S. et al. Medium-dose ultraviolet

(UV) A1 vs. narrowband UVB phototherapy in atopic eczema: a randomized

crossover study. Br J Dermatol 2009; 160: 652—658.

74.

Majoie I. M., Oldhoff J. M., van Weelden H. et al. Narrowband ultraviolet

B and medium-dose ultraviolet A1 are equally effective in the treatment of

moderate­ to severe atopic dermatitis. J Am Acad Dermatol 2009; 60: 77—84.

75.

Pugashetti R., Lim H. W., Koo J. Broadband UVB revisited: is the narrowband

UVB fad limiting our therapeutic options? J Dermatolog Treat 2010; 21: 326—330.

дерматит

76.

Tzaneva S., Kittler H., Holzer G. et al. 5-Methoxypsoralen plus ultraviolet

(UV) A is superior to medium-dose UVA1 in the treatment of severe atopic

dermatitis: a randomized crossover trial. Br J Dermatol 2010; 162: 655—660.

77.

Tominaga M., Tengara S., Kamo A. et al. Psoralen-ultraviolet A therapy alters

Атопический

epidermal Sema3A and NGF levels and modulates epidermal innervation in